Literature DB >> 3019921

Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist.

D A Handley, R G Van Valen, M K Melden, S Flury, M L Lee, R N Saunders.   

Abstract

Platelet activating factor (paf) given intravenously produces systemic hypotension in the rat. Similar effects can be induced using endotoxin or heat-aggregated IgG challenges, which are thought to involve endogenous paf release. Extending this concept, we have examined the ability of the paf antagonist SRI 63-072 to inhibit or reverse systemic hypotension induced with paf, heat-aggregated IgG or endotoxin 0111-B4 in rats. At 100 ng kg-1 paf, there occurred a 38.6 +/- 5.1% decrease in carotid mean arterial pressure (MAP) followed by a 3.2 +/- 0.7 min recovery period (RP) to return to normal pressure values. The ED50 of SRI 63-072 was 0.16 mg kg-1 i.v. (MAP) and 0.25 mg kg-1 (RP) when given 1-5 min before the paf challenge. Endotoxin (15 mg kg-1 i.v.) produced a hypotensive response (54 +/- 8% decrease in MAP) and a corresponding 80% decrease in mesenteric artery blood flow. When given 2-8 min after endotoxin, 1.0 mg kg-1 i.v. SRI 63-072 totally restored blood pressure and artery blood flow. SRI 63-072 similarly reversed heat-aggregated IgG (10 mg kg-1) induced reduction of MAP, with an ED50 of 0.05 mg kg-1 i.v. The observations that SRI 63-072 can inhibit or reverse systemic vascular effects produced from paf and other provocators of endogenous paf release strongly implicates paf as a common final mediator of hypotension and shock. As SRI 63-072 is a competitive receptor antagonist, the hypotensive effects of these provocators appear to be mediated by vascular receptors for paf.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3019921     DOI: 10.1016/0162-3109(86)90046-9

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  8 in total

1.  Effect of PAF-acether antagonists on active anaphylactic mouse paw edema.

Authors:  C Z Amorim; M G Henriques; V B Weg; R S Cordeiro; B B Vargaftig
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  The involvement of platelet activating factor in endotoxin-induced pulmonary platelet recruitment in the guinea-pig.

Authors:  L Beijer; J Botting; P Crook; A O Oyekan; C P Page; R Rylander
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

3.  Platelet-activating factor and hyperacute rejection. The effect of a platelet-activating factor antagonist, SRI 63-441, on rejection of xenografts and allografts in sensitized hosts.

Authors:  L Makowka; F A Chapman; D V Cramer; S G Qian; H Sun; T E Starzl
Journal:  Transplantation       Date:  1990-09       Impact factor: 4.939

4.  Endothelium-dependent vasodilator effects of platelet activating factor on rat resistance vessels.

Authors:  K Kamata; T Mori; K Shigenobu; Y Kasuya
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

5.  Pulmonary leukosequestration induced by hind limb ischemia.

Authors:  H Anner; R P Kaufman; L Kobzik; C R Valeri; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1987-08       Impact factor: 12.969

Review 6.  Platelet-activating factor in cardiovascular stress situations.

Authors:  R Rabinovici; T L Yue; G Feuerstein
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

7.  Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor.

Authors:  G Camussi; F Bussolino; G Salvidio; C Baglioni
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

8.  Lipopolysaccharide Cross-Tolerance Delays Platelet-Activating Factor-Induced Sudden Death in Swiss Albino Mice: Involvement of Cyclooxygenase in Cross-Tolerance.

Authors:  Shancy Petsel Jacob; Chikkamenahalli Lakshminarayana Lakshmikanth; Vyala Hanumanthareddy Chaithra; Titus Ruth Shantha Kumari; Chu-Huang Chen; Thomas M McIntyre; Gopal Kedihitlu Marathe
Journal:  PLoS One       Date:  2016-04-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.